4DMT reports FY2024 net loss of $160.9M; cash $505M; Phase 3 programs on track

4D Molecular Therapeutics, Inc.

2024-FY EPS reported -$2.98 revenue$37,000

Net loss of $160.9M in 2024 vs $100.8M in 2023; R&D expenses $141.3M (up 46% YoY).
Cash, cash equivalents and marketable securities of $505M as of Dec 31, 2024, funding operations into 2028.
Phase 3 4FRONT trials for 4D-150 in wet AMD to initiate March 2025 and Q3 2025; topline data expected H2 2027.
FDA aligned that a single Phase 3 trial is acceptable for BLA submission of 4D-150 in DME.
Pipeline focused on 4D-150 (wet AMD, DME) and 4D-710 (CF); paused other programs and terminated early-stage rare disease trials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.